Table 1.

Characteristics of CLL cases studied

CaseStage at diagnosis *Stage at study *Treatment Age/sexHemoglobin (g/dl)WBC (× 109/L)VH §CD38 (%) Phospho-ERK Calcium **sIgM ††Cell survival ‡‡Raft associated IgM §§
1C/IVC/IVCLB78/F11.32712.371716.51.623.30
2C/IIIC/IIINone65/M9.79911.10.70.941.121.3−1
3A/IA/INone81/F12.39710.640.11.931.161.7−8.50.9
4A/IC/IIICLB73/M12.92310.21.60.611.041.2−11
5A/IA/INone83/M14.2538.440.881.371.21.542.8
6A/0A/0CLB70/M14.6887.4811.731.011.11−10.57
7A/IA/ICLB + P56/M14.1916.5622.71.041.7−3.50.7
8B/IIIC/IVNone71/F13.2656.451.21.4N/A1.7N/A
9A/0A/0None81/F13.8415.686.26.41.11.4−4.51.2
10A/IIA/IINone64/M13244.866320.11.898.33.511.6
11C/IIIC/IIINone73/M10.9174.3408.891.824.5−0.5
12C/IVA/0CLB, CLB + P74/F11.5164.15401071.722.432.5
13C/IVC/IVF + C81/M63002.480.431.772.7318.5
14B/IIB/IICLB, F, CHOP61/M11.96124094.31.699.823.59.8
15B/IIIB/IIICLB75/F10.81101.41529.441.251.1214
16A/IC/IVCLB79/F8.14470.71612.33N/A1.341.5
17C/IIIA/ICLB68/M11.91360.664198.922.211.536.2
18A/IC/IIICLB38/M10.31360.42660.91.131.8−0.50.9
19A/IA/ICLB, F71/F11.61100.343.46.391.312.53
20B/IB/ICLB, F61/M11.62310624.91.11.21.54.2
21B/IIB/IICLB, F63/M14.424805113.71.072.74
22A/IA/INone69/M13.59900.64.391.422.613.573.1
23B/IIIB/IIICLB72/M9.125801413.81.031.3513.8
  • * Binet/Rai clinical stages.

  • CLB, chlorambucil; P, prednisolone; F, fludarabine; C, cyclophosphamide; H, Adriamycin; O, vincristine.

  • Hemoglobin and WBC at time of study.

  • § Percent deviation from germ line.

  • Percentage of CD38+19+ cells.

  • Density of phospho-ERK band after BCR cross-linking as a ratio of that present in unstimulated cells.

  • ** [Ca2+] in cells cross-linked with anti-IgM for 5 minutes as ratio of that present without cross-linking.

  • †† Mean fluorescence intensity of sIgM as a ratio of that of isotypic control.

  • ‡‡ Change in percent viable cells following BCR cross-linking with F(ab′)2 anti-μ.

  • §§ Mean density of raft-associated IgM following BCR engagement (10 minutes) as a ratio of that present in unstimulated cells.